At a glance
ClinicalIndex Comparison RecordPhase 2Active· 25 enrolled
Drug / intervention
Docetaxel +1 moredrug
Likely dose
Docetaxel 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery
In Brief
A Phase 2 clinical trial evaluating Docetaxel and Carboplatin for Breast Cancer. Active but no longer recruiting, targeting 25 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2ActiveOverdue
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartNov 2015
Primary CompletionJun 2019
Study CompletionSep 2025
TodayJul 2026
First PostedSep 14, 2015
Enrollment StartNov 1, 2015
Primary CompletionJun 25, 2019
Study CompletionSep 1, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 10.8 years ago
Interventions
Docetaxeldrug
Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
Carboplatindrug
Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6